BPC-157 had a bigger regulatory year in 2026 than in any year before it. FDA pulled it off one list in April, an FDA advisory committee recommended it for another in July, and a wave of headlines followed that described both events in very different ways. Some said the peptide was approved, others said it was banned, and neither is accurate.
This guide walks through what actually happened, using FDA’s own records, and separates the three legal steps that most coverage blends together. It also explains why none of these changes touch research-use-only supply, and what to watch for as FDA decides its next move.
The Short Answer
BPC-157 is not an FDA-approved drug, and it is not on the list of bulk substances that pharmacies may legally compound. In April 2026, FDA took it off its Category 2 list after the people who nominated it withdrew their nominations. In July, an FDA advisory committee voted 8 to 6 to recommend adding it to that list.
That vote did not change the law. FDA still has to write and finalize a rule, and as of this writing it has not set a timeline. Whether research suppliers can sell BPC-157 is a separate legal question, and we cover it below.
The 2026 Timeline
BPC-157’s status has changed twice in three years, and it is likely to change again.
| When | What happened |
|---|---|
| 2023 | FDA placed BPC-157 in Category 2, the list of bulk substances it flagged as possibly presenting significant safety risks in compounding. |
| April 2026 | FDA removed BPC-157 and 16 other substances from Category 2 after their nominators withdrew the nominations. |
| July 23 to 24, 2026 | FDA’s Pharmacy Compounding Advisory Committee voted to recommend BPC-157 and five other peptides for the 503A Bulks List. |
| August 24, 2026 | FDA issued warning letters to five online peptide sellers, posted publicly on September 1. |
| Before end of February 2027 | A second advisory committee meeting is scheduled for five more peptides, including Melanotan II and GHK-Cu. |
| No date set | FDA rulemaking on whether to actually add BPC-157 to the 503A Bulks List. |
Three Events That Keep Getting Collapsed Into One
Most confusion about BPC-157 comes from treating three separate legal events as one. Each one means something different, and only the last one makes BPC-157 compoundable.
Removal From Category 2 (April 2026)
Category 2 is FDA’s list of nominated bulk substances that may present significant safety risks. A substance in Category 2 effectively cannot be compounded under FDA’s interim policy. FDA’s own page now lists BPC-157 under nominated but withdrawn, meaning the parties who nominated it pulled their nominations.
Removal did not erase FDA’s concerns. The same page still notes that FDA identified no, or only limited, safety-related information for BPC-157’s proposed routes of administration. Removal also did not place BPC-157 in Category 1, the interim tier that would allow compounding while FDA decides.
The Advisory Committee Recommendation (July 23, 2026)
FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 for one nominated use, ulcerative colitis. It voted 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A Bulks List. The committee is advisory, so its vote is a recommendation to FDA, not a decision.
Placement on the 503A Bulks List (Pending)
This is the only step that would let licensed pharmacies compound BPC-157. FDA develops the list through notice-and-comment rulemaking: a proposed rule, a public comment period, then a final rule. Until that process finishes, the July vote did not amend the 503A Bulks List.
What the July Vote Did and Didn’t Do
The committee recommended six of the seven peptides it reviewed and rejected one.
| Peptide | Vote | Outcome |
|---|---|---|
| BPC-157 | 8 to 6, 1 abstention | Recommended |
| KPV | 8 to 6, 1 abstention | Recommended |
| TB-500 | 8 to 6, 1 abstention | Recommended |
| MOTs-C | 7 to 5, 2 abstentions | Recommended |
| Semax | Narrow margin | Recommended |
| Epitalon | Narrow margin | Recommended |
| Emideltide (DSIP) | Failed | Not recommended |
Vote counts are from McDermott and AJMC.
Two details matter more than the tallies. First, FDA’s own scientists recommended against all seven. In its briefing document, FDA proposed that BPC-157 not be included on the list, and the committee voted against that staff recommendation.
Second, the vote did nothing on its own. No peptide was added to the list, none became an approved drug, and FDA must still decide whether to accept the recommendation.
Why So Many Pages Get This Wrong
Search for BPC-157’s legal status and you will find pages that contradict each other. The errors fall into three patterns.
- Calling the vote an approval. Some headlines say FDA “cleared” or “approved” BPC-157. FDA approved nothing, and attorneys tracking the issue have warned that the votes should not be described as FDA approval in marketing.
- Telling the Category 2 story backwards. Some pages still claim the 2026 changes moved BPC-157 into Category 2. It was placed there in 2023 and removed in 2026.
- Treating removal as permission. Leaving Category 2 is not the same as reaching Category 1 or the 503A Bulks List. A substance can sit outside every list and still not be lawfully compoundable.
When a page skips the difference between these events, the safest move is to check FDA’s own pages, linked throughout this post.
What This Means for Research Suppliers
The 503A Bulks List governs one thing: traditional pharmacies compounding medications for individual patients with a prescription. Research suppliers operate outside that framework. A final rule adding BPC-157 to the list would change what pharmacies can prepare, not what laboratories can purchase.
That does not make a research-use-only label a legal shield. In its August 2026 warning letters to five peptide sellers, FDA looked past the label at the surrounding website content. Where that content described effects on the body, FDA treated the products as unapproved drugs.
Oakspire Research is built around that line. We supply compounds for laboratory and research use only, we publish no human-use claims or dosing information, and every batch is independently tested with a certificate of analysis published before it ships. The compounds discussed in this post that appear in our catalog are BPC-157, BPC-157 + TB-500, MOTs-C, Epithalon, Melanotan II, CJC-1295 + Ipamorelin, and Selank.
The Other Compounds in This Story
BPC-157 was one of 17 substances FDA’s page lists as withdrawn from Category 2. Several others are moving through the same process.
Recommended in July: TB-500, MOTs-C, and Epitalon
TB-500 passed 8 to 6 with one abstention, and MOTs-C passed 7 to 5 with two abstentions. Epitalon passed on the second day of the meeting. Like BPC-157, all three now wait on FDA rulemaking, with no date set.
Still Waiting: Melanotan II
Melanotan II was also withdrawn from Category 2 but was not on the July agenda. It is among five peptides, along with LL-37, GHK-Cu, Dihexa acetate, and PEG-MGF, scheduled for a second meeting before the end of February 2027.
Rejected: DSIP
The committee voted against recommending emideltide, also called DSIP, the only one of the seven it turned down.
Three more compounds on FDA’s withdrawn list, CJC-1295, Ipamorelin, and Selank, were not reviewed in July. Ipamorelin acetate also remains in Category 2 under FDA’s separate 503B policy for outsourcing facilities.
What to Watch Next
Four developments will decide where BPC-157 lands, roughly in this order.
- FDA’s response to the recommendation. FDA can accept or reject the committee’s vote, and it is not bound by it.
- A proposed rule. If FDA moves forward, it will publish a proposal to add BPC-157 to the 503A Bulks List, which opens a public comment period.
- A final rule. Only a final rule would make BPC-157 compoundable by licensed pharmacies.
- The second advisory meeting. The committee is due to review Melanotan II, GHK-Cu, and three other peptides before the end of February 2027.
We will update this post as each step happens.
Frequently Asked Questions
Is BPC-157 FDA approved?
No. BPC-157 has never been approved by FDA for any use. The July 2026 advisory vote concerned compounding eligibility, which is a different process from drug approval.
Can pharmacies compound BPC-157 right now?
No. BPC-157 is not on the 503A Bulks List, and the advisory committee’s recommendation does not add it. Compounding would require FDA to finalize a rule first.
Did the July vote change anything for research supply?
No. The 503A Bulks List applies to pharmacy compounding for patients, not to research-use-only supply. What FDA does watch is how sellers market these compounds, as its 2026 warning letters show.
When will FDA decide?
FDA has not announced a timeline. Rulemaking requires a proposed rule, a comment period, and a final rule, and that process often takes many months.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
- FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- FDA Briefing Document, July 2026 PCAC Meeting
- FDA: Warning Letters
- McDermott: PCAC Backs Majority of Peptides in Two-Day Public Meeting
- AJMC: FDA Panel Backs 6 Peptides for Compounding
- Buchanan Ingersoll & Rooney: FDA Advisory Committee Voted Yes on Six Peptides. Now What?
- Tech Times: FDA Panel Backs Peptide BPC-157 for Compounding in 8-6 Vote
This article is for general informational purposes only and is not legal advice. All Oakspire Research products are supplied for laboratory and research use only and are not intended for human or animal consumption.